General Information of Drug (ID: DMN3S1B)

Drug Name
ABT-229 Drug Info
Synonyms
Alemcinal; ABT-229; UNII-5DS173ODI4; 5DS173ODI4; ABBOTT-81229.0; 150785-53-8; A-81229; Alemcinal (USAN/INN); CHEMBL300049; ABT229; GTPL1444; BDBM86685; ABT 229; D02801; 8,9-didehydro-N-demethyl-9-deoxo-4', 6, 12-trideoxy-6,9-epoxy-N-ethylerythromycin
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Phase 2 [1]
Cross-matching ID
PubChem CID
9918079
CAS Number
CAS 150785-53-8
TTD Drug ID
DMN3S1B

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
VESNARINONE DMBKX3C Cardiac failure BD10-BD13 Approved [3]
M100907 DM7ZFBA Sleep-wake disorder 7A00-7B2Z Phase 3 [4]
HP-184 DMNOMV2 Multiple sclerosis 8A40 Phase 2 [5]
NITD609 DMQHBSX Malaria 1F40-1F45 Phase 2 [6]
ISOQUINE DMR17YI Malaria 1F40-1F45 Phase 1 [7]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMC8935 N. A. N. A. Patented [8]
Isoindoline derivative 5 DMIUTQW N. A. N. A. Patented [9]
Isoindoline derivative 3 DM2MYL9 N. A. N. A. Patented [9]
Isoindoline derivative 4 DMP1NKI N. A. N. A. Patented [9]
Isoindoline derivative 2 DMTE0S3 N. A. N. A. Patented [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated potassium channel Kv11.1 (KCNH2) TTQ6VDM KCNH2_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1444).
2 9-Dihydroerythromycin ethers as motilin agonists--developing structure-activity relationships for potency and safety. Bioorg Med Chem. 2010 Nov 1;18(21):7651-8.
3 Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5.
4 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
5 Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
6 Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
7 Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15.
8 Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
9 The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.